← Back to Patent Explorer
US4786509A Expired / Lapsed US ⏱️ 0.0 years remaining

Dry sustained release theophylline oral formulation

Assignee: Merck Sharp & Dohme LLC
•
Filing: 1987-05-18
•
Granted: 1988-11-22
•
Expires: 2007-05-18
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A sustained release theophylline containing oral dosage formulation comprising theophylline containing micropellets coated with from about 0.5% to about 2% by weight of a pharmaceutically acceptable water-insoluble film former, preferably ethyl cellulose and having first order release. The formulation is an improvement over theophylline containing micropellets coated with two film formers which have zero order release. The oral dosage formulation has superior non-fasting release and absorption characteristics when compared to the zero order release formulation.

Inventors

  • 👤 Richard Chang
  • 👤 Robert P. Giannini
  • 👤 Charles Hsaio

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-02 23:50
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/48; A61K9/50; A61K9/5073; A61K9/5078; A61K31/00; A61K31/33; A61K31/395; A61K31/495; A61K31/505; A61K31/519; A61K31/52

Claims Analysis

Total Claims: 8
Claim 1
Independent Claim 47 words
A first order sustained release theophylline composition comprising theophylline-containing micropellets having on the outside surface thereof a coating consisting of a pharmaceutically acceptable water-insoluble single film former present in an amount of from about 0.5% to about 2.0% by weight based on the weight of said micropellets.
Claim 2
Dependent Claim 47 words
A first order sustained release theophylline composition comprising theophylline-containing micropellets having on the outside surface thereof a coating consisting of a pharmaceutically acceptable water-insoluble single film former present in an amount of from about 0.5% to about 2.0% by weight based on the weight of said micropellets.
Claim 3
Dependent Claim 11 words
A composition of claim 1 wherein said coating is ethyl cellulose.
Claim 4
Dependent Claim 15 words
A composition of claim 2 wherein the ethyl cellulose coating is about 1.5% by weight.
Claim 5
Dependent Claim 67 words
A first-order sustained release unit dosage form of theophylline comprising an easily openable capsule having therein a plurality of theophylline-containing micropellets, the amount of micropellets in said capsule comprising a dosage unit of theophylline, wherein each of said micropellets have a coating thereon of from about 0.5% to about 2.0% by weight based on the weight of said micropellets of a single pharmaceutically acceptable water-insoluble film former.
Claim 6
Dependent Claim 67 words
A first-order sustained release unit dosage form of theophylline comprising an easily openable capsule having therein a plurality of theophylline-containing micropellets, the amount of micropellets in said capsule comprising a dosage unit of theophylline, wherein each of said micropellets have a coating thereon of from about 0.5% to about 2.0% by weight based on the weight of said micropellets of a single pharmaceutically acceptable water-insoluble film former.
Claim 7
Dependent Claim 14 words
A unit dosage form of claim 4 wherein the film former is ethyl cellulose.
Claim 8
Dependent Claim 18 words
A unit dosage form of claim 5 wherein the amount of ethylcellulose coating is about 1.5% by weight.

References Cited (Backward Citations)

US3835221A Cited
US4083949A Cited
US4587118A Cited
US4692337A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1991-11-22 1992-05-23 1992-11-22 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1995-11-22 1996-05-23 1996-11-22 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1999-11-22 2000-05-23 2000-11-22 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag